John F Forbes
John F Forbes
Professor of Surgical Oncology University of Newcastle
Verified email at anzbctg.org
TitleCited byYear
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 365 (9472), 1687-1717, 2005
54502005
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 366 (9503), 2087-2106, 2005
44982005
Tamoxifen for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 351 (9114), 1451-1467, 1998
31261998
Genome-wide association study identifies novel breast cancer susceptibility loci
DF Easton, KA Pooley, AM Dunning, PDP Pharoah, D Thompson, ...
Nature 447 (7148), 1087, 2007
24032007
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer
A Howell, J Cuzick, M Baum, A Buzdar, M Dowsett, JF Forbes, ...
Lancet 365 (9453), 60-62, 2005
22032005
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ...
Annals of oncology 24 (9), 2206-2223, 2013
21312013
Polychemotherapy for early breast cancer: an overview of the randomised trials
Early Breast Cancer Trialists' Collaborative Group
The Lancet 352 (9132), 930-942, 1998
17981998
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial.
DJ Adam, JD Beard, T Cleveland, J Bell, AW Bradbury, JF Forbes, ...
Lancet (London, England) 366 (9501), 1925-1934, 2005
16042005
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer
Breast International Group (BIG) 1-98 Collaborative Group
New England Journal of Medicine 353 (26), 2747-2757, 2005
15882005
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
A Goldhirsch, JN Ingle, RD Gelber, AS Coates, B Thürlimann, HJ Senn, ...
Annals of oncology 20 (8), 1319-1329, 2009
15772009
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC …
A The
The Lancet 359 (9324), 2131-2139, 2002
15392002
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
C Davies, H Pan, J Godwin, R Gray, R Arriagada, V Raina, M Abraham, ...
The Lancet 381 (9869), 805-816, 2013
14292013
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ...
Annals of oncology 26 (8), 1533-1546, 2015
11192015
Overview of the main outcomes in breast-cancer prevention trials
J Cuzick, T Powles, U Veronesi, J Forbes, R Edwards, S Ashley, P Boyle
The Lancet 361 (9354), 296-300, 2003
10882003
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98
AS Coates, A Keshaviah, B Thurlimann, H Mouridsen, L Mauriac, ...
Journal of clinical oncology 25 (5), 486-492, 2007
9552007
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
RC Coombes, LS Kilburn, CF Snowdon, R Paridaens, RE Coleman, ...
The Lancet 369 (9561), 559-570, 2007
9442007
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
T Arimidex
The lancet oncology 9 (1), 45-53, 2008
8812008
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
M Dowsett, J Cuzick, J Ingle, A Coates, J Forbes, J Bliss, M Buyse, ...
Journal of Clinical Oncology 28 (3), 509-518, 2009
7932009
SYSTEMIC TREATMENT OF EARLY BREAST-CANCER BY HORMONAL, CYTOTOXIC, OR IMMUNE THERAPY-133 RANDOMIZED TRIALS INVOLVING 31000 RECURRENCES AND 24000 DEATHS AMONG 75000 WOMEN. 2.
O Abe, R Abe, K Asaishi, K Enomoto, T Hattori, Y Ino, K Kikuchi, ...
Lancet 339 (8785), 71-85, 1992
7891992
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women …
P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, R Gray, ...
Lancet (London, England) 383 (9935), 2127-2135, 2014
7872014
The system can't perform the operation now. Try again later.
Articles 1–20